Free access

Research Article

1 June 2018

Intravitreal aflibercept versus intravitreal ranibizumab in patients with age-related macular degeneration: a comparative effectiveness study

Authors: Cornelis Smit, Karin Wiertz-Arts, and Ewoudt MW van de Garde [email protected]Author Info & Affiliations

Publication: J. Comp. Eff. Res.

Volume 7, Number 6

https://doi.org/10.2217/cer-2017-0099

PDF OtherFormats

Abstract

Aim: A hospital-wide, unselected switch of ranibizumab to aflibercept in treatment of age-related macular degeneration (AMD) allowed us to compare the clinical effectiveness of these agents. Method: In a single-center before–after, observational study design new AMD-patients started with aflibercept treatment in 2013–2014 were compared with a control group of AMD-patients on ranibizumab before the switch. Results: The mean difference in visual acuity (in logMAR units) after 1 year was comparable (+0.012 [aflibercept, n = 37] vs +0.17 [ranibizumab, n = 30], p = 0.154). However, the aflibercept-group did receive more intravitreal injections (5.8 vs 4.7 injections, p = 0.004) and were treated longer (265.7 vs 197.7 days; p = 0.011). Conclusion: With no difference in clinical effectiveness, longer treatment intervals for aflibercept should be investigated.

Formats available

You can view the full content in the following formats:

View PDF View Full Text

References

Papers of special note have been highlighted as: • of interest

1.

Sox HC, Greenfield S. Comparative effectiveness research: a report from the Institute of Medicine. Ann. Intern. Med. 151(3), 203–205 (2009).

2.

Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N. Engl. J. Med. 358(24), 2606–2617 (2008).

• Elaborate overview of the pathophysiology and management of age-related macular degeneration.

3.

Yancopoulos GD. Clinical application of therapies targeting VEGF. Cell 143(1), 13–16 (2010).

4.

Group CR, Martin DF, Maguire MG et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 364(20), 1897–1908 (2011).

5.

Heier JS, Brown DM, Chong V et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119(12), 2537–2548 (2012).

• The VIEW trials, large, multicenter studies that prospectively compared monthly ranibizumab with several aflibercept dosing regimens, demonstrated that bimonthly aflibercept had comparable efficacy to monthly ranibizumab in a prospective trial setting.

6.

Cho H, Shah CP, Weber M et al. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab. Br. J. Ophthalmol. 97(8), 1032–1035 (2013).

7.

Holladay JT. Proper method for calculating average visual acuity. J. Refract. Surg. 13(4), 388–391 (1997).

8.

Johnston SS, Wilson K, Huang A, Smith D, Varker H, Turpcu A. Retrospective analysis of first-line anti-vascular endothelial growth factor treatment patterns in wet age-related macular degeneration. Adv. Ther. 30(12), 1111–1127 (2013).

9.

Reich O, Bachmann LM, Faes L et al. Anti-VEGF treatment patterns and associated health care costs in Switzerland: findings using real-world claims data. Risk Manag. Healthc. Policy 8, 55–62 (2015).

10.

Lotery AJ, Regnier S. Patterns of ranibizumab and aflibercept treatment of central retinal vein occlusion in routine clinical practice in the USA. Eye (Lond.) 29(3), 380–387 (2015).

11.

Böhni SC, Bittner M, Howell JP, Bachmann LM, Faes L, Schmid MK. Comparison of Eylea^® with Lucentis^® as first-line therapy in patients with treatment-naïve neovascular age-related macular degeneration in real-life clinical practice: retrospective case-series analysis. BMC Ophthalmol. 15, 109 (2015).

12.

Yuzawa M, Fujita K, Wittrup-Jensen KU et al. Improvement in vision-related function with intravitreal aflibercept: data from Phase III studies in wet age-related macular degeneration. Ophthalmology 122(3), 571–578 (2015).

13.

Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br. J. Ophthalmol. 92(5), 667–668 (2008).

14.

Ohnaka M, Nagai Y, Sho K et al. A modified treat-and-extend regimen of aflibercept for treatment-naïve patients with neovascular age-related macular degeneration. Graefe's Arch. Clin. Exp. Ophthalmol. 255(4), 657–664 (2017).

15.

Takayama K, Kaneko H, Sugita T et al. One-year outcomes of 1 + pro re nata versus 3 + pro re nata intravitreal aflibercept injection for neovascular age-related macular degeneration. Ophthalmologica 237(2), 105–110 (2017).

16.

Mori R, Tanaka K, Haruyama M, Kawamura A, Furuya K, Yuzawa M. Comparison of pro re nata versus bimonthly injection of intravitreal aflibercept for typical neovascular age-related macular degeneration. Ophthalmologica 238(1–2), 17–22 (2017).

|